Last10K.com

Ac Immune Sa (ACIU) SEC Filing 20-F Annual Report for the fiscal year ending Friday, December 31, 2021

Ac Immune Sa

CIK: 1651625 Ticker: ACIU

View differences made from one year to another to evaluate Ac Immune Sa's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ac Immune Sa.

Continue

Assess how Ac Immune Sa's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ac Immune Sa's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Equity
Consolidated Statements Of Comprehensive Income/(Loss)
Consolidated Statements Of Income/(Loss)
Asset Acquisition
Asset Acquisition (Details)
Asset Acquisition (Tables)
Basis Of Preparation
Basis Of Preparation (Details)
Capital Risk Management
Cash And Cash Equivalents And Financial Assets
Cash And Cash Equivalents And Financial Assets (Tables)
Cash And Cash Equivalents And Financial Assets, Cash And Cash Equivalents (Details)
Cash And Cash Equivalents And Financial Assets, Cash And Cash Equivalents And Short-Term Financial Assets (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Commitments And Contingencies (Tables)
Contract Revenues
Contract Revenues (Tables)
Contract Revenues, A-Syn And Tdp-43 Pet Tracers - 2016 Agreement With Biogen (Details)
Contract Revenues, Anti-Abeta Antibody In Ad - 2006 Agreement With Genentech (Details)
Contract Revenues, Anti-Tau Antibody In Ad - 2012 Agreement With Genentech (Details)
Contract Revenues, Changes In Contract Assets And Liabilities (Details)
Contract Revenues, Contract Revenue Attributable To Licensing Arrangements (Details)
Contract Revenues, Grant From The Target Als Foundation (Details)
Contract Revenues, Grants From The Michael J. Fox Foundation (Details)
Contract Revenues, Morphomer Tau Small Molecule - 2018 License Agreement With Eli Lilly And Company (Details)
Contract Revenues, Recognized Revenues (Details)
Contract Revenues, Tau Vaccine In Ad - 2014 Agreement With Janssen Pharmaceuticals (Details)
Contract Revenues, Tau-Pet Imaging Agent -2014 Agreement With Life Molecular Imaging (Formerly Piramal Imaging Sa) (Details)
Earnings Per Share
Earnings Per Share (Details)
Earnings Per Share (Tables)
Expenses By Category
Expenses By Category (Details)
Expenses By Category (Tables)
Financial Instruments And Risk Management
Financial Instruments And Risk Management (Details)
Financial Instruments And Risk Management (Tables)
General Information
General Information (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes, Summary Of Income Tax Expense (Details)
Income Taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses And Unused Tax Credits (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets, Carrying Amount And Net Book Value (Details)
Other Current Receivables
Other Current Receivables (Details)
Other Current Receivables (Tables)
Prepaid Expenses And Accrued Income
Prepaid Expenses And Accrued Income (Details)
Prepaid Expenses And Accrued Income (Tables)
Property, Plant And Equipment
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Related-Party Transactions
Related-Party Transactions (Details)
Related-Party Transactions (Tables)
Retirement Benefit Plan
Retirement Benefit Plan (Tables)
Retirement Benefit Plan, Actuarial Assumptions And Sensitivity Analysis (Details)
Retirement Benefit Plan, Change In Net Defined Benefit Liability (Details)
Retirement Benefit Plan, Change In Other Comprehensive Loss (Details)
Retirement Benefit Plan, Changes In Defined Benefit Obligation (Details)
Retirement Benefit Plan, Changes In Fair Value Of Plan Assets (Details)
Retirement Benefit Plan, Summary Of Benefit Plan (Details)
Right-Of-Use Assets And Lease Liabilities
Right-Of-Use Assets And Lease Liabilities (Details)
Right-Of-Use Assets And Lease Liabilities (Tables)
Share Capital
Share Capital (Tables)
Share Capital, At The Market Equity Offering (Details)
Share Capital, Capital Structure (Details)
Share Capital, Conditional Share Capital For Bonds And Similar Debt Instruments (Details)
Share Capital, Conditional Share Capital For Employee Benefit Plans (Details)
Share Capital, Convertible Note Agreement (Details)
Share Capital, Shelf Registration Statement (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation, Non-Vested Share Awards (Details)
Share-Based Compensation, Outstanding Options, Range Of Exercise Prices And Expiration Dates (Details)
Share-Based Compensation, Plans Outstanding (Details)
Share-Based Compensation, Weighted Average Exercise Prices (Details)
Share-Based Compensation, Weighted Average Grant Date Fair Value And Assumptions (Details)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies, Functional And Reporting Currency (Details)
Summary Of Significant Accounting Policies, Income Taxes (Details)
Summary Of Significant Accounting Policies, Property, Plant And Equipment (Details)
Summary Of Significant Accounting Policies, Right-Of-Use Assets And Lease Liabilities (Details)
Summary Of Significant Accounting Policies, Segment Reporting (Details)
Trade And Other Payables And Accrued Expenses
Trade And Other Payables And Accrued Expenses (Details)
Trade And Other Payables And Accrued Expenses (Tables)
Ticker: ACIU
CIK: 1651625
Form Type: 20-F Annual Report
Accession Number: 0001140361-22-010439
Submitted to the SEC: Tue Mar 22 2022 7:02:26 AM EST
Accepted by the SEC: Tue Mar 22 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aciu/0001140361-22-010439.htm